Skip to main content

Scientific Advisory Board

Hepion leadership brings deep experience in the development and commercialization of targeted antiviral therapies for indications of important unmet need.

Philippe Gallay, Ph.D.

Scientific Advisory Board

Dr. Gallay is Professor, Department of Immunology and Microbial Science at the Scripps Research Institute in La Jolla (San Diego), California. Dr. Gallay holds a Swiss Federal Diploma (MS), from the Institute of Biochemistry, Epalinges, Switzerland and a PhD from Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.  Dr. Gallay’s research program examines the molecular basis of HIV, HCV, and HBV pathogenesis, including characterization of host proteins modulating viral replication, such as various cyclophilins (Host Targeting Antivirals). Learn More >>

Stephen Harrison, M.D.

Scientific Advisory Board

Dr. Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford. He is also the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research. Dr. Harrison is a peer-reviewer for more than 20 medical journals. He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with more than 200 peer reviewed publications in these fields. Dr. Harrison previously served as a Professor of Medicine at the Uniformed Services University of the Health Sciences. Learn More >>